Literature DB >> 8538674

A transgenic mouse model of the slow-channel syndrome.

C M Gomez1, B B Bhattacharyya, P Charnet, J W Day, C Labarca, R L Wollmann, E H Lambert.   

Abstract

To investigate the effect of acetylcholine receptor (AChR) mutations on neuromuscular transmission and to develop a model for the human neuromuscular disease, the slow-channel syndrome, we generated transgenic mice with abnormal AChRs using a delta subunit with a mutation in the ion channel domain. In three transgenic lines, nerve-evoked end-plate currents and spontaneous miniature end-plate currents (MEPCs) had prolonged decay phases and MEPC amplitudes were reduced by 33%. Single nerve stimuli elicited repetitive compound muscle action potentials in vivo. Transgenic mice were abnormally sensitive to the neuromuscular blocker, curare. These observations demonstrate that we can predictably alter AChR function, synaptic responses, and muscle fiber excitation in vivo by overexpressing subunits containing well-defined mutations. Furthermore these data support the hypothesis that the electrophysiological findings in the neuromuscular disorder, the slow-channel syndrome, are due to mutant AChRs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8538674     DOI: 10.1002/(SICI)1097-4598(199601)19:1<79::AID-MUS11>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

1.  Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome.

Authors:  Jason S Groshong; Melissa J Spencer; Bula J Bhattacharyya; Elena Kudryashova; Bhupinder P S Vohra; Roberto Zayas; Robert L Wollmann; Richard J Miller; Christopher M Gomez
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 2.  Nicotinic acetylcholine receptors in health and disease.

Authors:  J Lindstrom
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

3.  Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction.

Authors:  C M Gomez; R Maselli; J E Gundeck; M Chao; J W Day; S Tamamizu; J A Lasalde; M McNamee; R L Wollmann
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

4.  Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions.

Authors:  G E Grajales-Reyes; C A Báez-Pagán; H Zhu; J G Grajales-Reyes; M Delgado-Vélez; W F García-Beltrán; C A Luciano; O Quesada; R Ramírez; C M Gómez; J A Lasalde-Dominicci
Journal:  Pharmacogenomics J       Date:  2012-06-12       Impact factor: 3.550

Review 5.  Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.

Authors:  José David Otero-Cruz; Carlos Alberto Báez-Pagán; Luisamari Dorna-Pérez; Gary Emanuel Grajales-Reyes; Rosaura Teresa Ramírez-Ordoñez; Carlos A Luciano; Christopher Manuel Gómez; José Antonio Lasalde-Dominicci
Journal:  P R Health Sci J       Date:  2010-03       Impact factor: 0.705

Review 6.  Animal Models of the Neuromuscular Junction, Vitally Informative for Understanding Function and the Molecular Mechanisms of Congenital Myasthenic Syndromes.

Authors:  Richard G Webster
Journal:  Int J Mol Sci       Date:  2018-04-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.